Regorafenib in the treatment of colorectal cancer.

about

Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.A novel multikinase inhibitor R8 exhibits potent inhibition on cancer cells through both apoptosis and autophagic cell death.

P2860

Q38805622-CC9162A2-E15A-4FBE-9A6D-ED7514D372F7 Q44869860-0FFB5687-6CFC-42FB-8DA5-608A033D5EAC

P2860

Regorafenib in the treatment of colorectal cancer.

Item

http://www.wikidata.org/entity/Q38630817

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Regorafenib in the treatment of colorectal cancer.

@en

type

Item

label

Regorafenib in the treatment of colorectal cancer.

@en

prefLabel

Regorafenib in the treatment of colorectal cancer.

@en

P1476

Regorafenib in the treatment of colorectal cancer.

@en

P2093

Axel Grothey

http://www.w3.org/2001/XMLSchema#string

Neil Majithia

http://www.w3.org/2001/XMLSchema#string

P2860

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cancer statistics, 2015

Tumor angiogenesis: therapeutic implications

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Vascular-specific growth factors and blood vessel formation

Rational design of inhibitors that bind to inactive kinase conformations

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

P304

137-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2016.1118054

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26559195

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

Regorafenib in the treatment of colorectal cancer.

about

P2860

P2860

Regorafenib in the treatment of colorectal cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921